NEC Baby Formula Lawsuit 2026: Similac & Enfamil Claims, MDL Update & Who Qualifies

Hundreds of lawsuits allege that cow's-milk-based infant formulas — Similac products made by Abbott Laboratories and Enfamil products made by Mead Johnson — increased the risk of necrotizing enterocolitis (NEC), a devastating intestinal disease, in premature infants. The federal cases are consolidated in MDL No. 3120 in the Northern District of Illinois, where bellwether trials are scheduled or underway. Compensation varies widely by case, and most settlements are confidential.

NEC is every NICU parent's nightmare: a premature baby's intestines become inflamed and, in severe cases, tissue dies — requiring emergency surgery or, too often, ending in death. For years, neonatology research has linked cow's-milk-based formula feeding in preterm infants with higher NEC rates compared with human breast milk. The lawsuits allege that the manufacturers knew of this research and failed to warn hospitals and parents, continuing to market their preterm formulas without adequate NEC warnings.

This litigation is distinct from most product cases because the victims are newborns and the plaintiffs are their parents. Below is the full picture for 2026: what NEC is, what the lawsuits claim, where the MDL stands, which products are named, and who may qualify to file.

For more plain-language explainers on money, insurance, and the law, follow the Problem Solved channel.

What Necrotizing Enterocolitis (NEC) Is

Necrotizing enterocolitis — NEC — is a serious gastrointestinal disease that primarily strikes premature and low-birth-weight infants. Bacteria invade the wall of the immature intestine, causing inflammation that can progress to tissue death (necrosis). Symptoms include feeding intolerance, abdominal swelling, bloody stools, and lethargy. Diagnosis is confirmed by abdominal X-ray showing pneumatosis intestinalis — gas within the bowel wall.

Treatment escalates with severity: antibiotics and bowel rest for milder cases, surgery to remove dead intestinal tissue for severe ones. Babies who survive severe NEC can face lifelong complications — short-bowel syndrome, developmental delays, and the need for prolonged parenteral nutrition. It is one of the leading causes of death among very-low-birth-weight infants in neonatal intensive care units, which is why the feeding question matters so much in the NICU.

The Claims Against the Formula Makers

The lawsuits name two manufacturers. Abbott Laboratories makes the Similac line of preterm and specialized infant formulas; Mead Johnson (a Reckitt subsidiary) makes the Enfamil line. Plaintiffs allege that both companies knew — from published medical literature and their own research — that cow's-milk-based products carry an elevated NEC risk for premature infants, yet marketed their preterm formulas to hospitals and parents without warning of that risk.

The core legal theory is failure to warn, not that formula itself is inherently defective for all babies. Plaintiffs argue the companies should have disclosed the NEC risk so that hospitals and parents could make informed feeding decisions — including the option of donor human milk or human-milk fortifiers. The manufacturers have disputed these claims, and some individual cases have gone to trial with mixed results, which is typical of hard-fought mass-tort litigation before the science is fully settled in court.

MDL Status and Bellwether Trials in 2026

The federal cases are centralized in MDL No. 3120 before the U.S. District Court for the Northern District of Illinois. As with other MDLs, this is not a class action — each family's case remains individual while the court coordinates discovery, expert testimony, and pretrial rulings across all cases. Bellwether trials — representative cases tried first to test the evidence and gauge jury reactions — are scheduled or underway, and their outcomes will heavily influence settlement negotiations for the remaining docket.

State-court cases are proceeding in parallel, and some have already produced verdicts that drew national attention. Because individual trial results in this litigation have varied, the bellwether process in the MDL is the event both sides are watching most closely in 2026: it is the closest thing to a market price for these claims before any global settlement discussion. Our overview of NEC baby formula lawsuits and how to file tracks the procedural posture in more detail.

Which Products Are Named

The litigation focuses on cow's-milk-based formulas marketed for premature or medically fragile infants — the products used in NICUs — rather than standard term-infant formula. On the Abbott side, the Similac preterm and specialized lines are at issue; on the Mead Johnson side, the Enfamil preterm and specialized lines. The specific product names matter because the claims concern how these products were fed to premature infants in hospital settings.

Parents often do not know exactly which formula their baby received in the NICU — and that is normal. Hospital feeding records, which your lawyer can obtain, document precisely what was given and when. If your premature infant was fed formula in the NICU and developed NEC, do not assume you lack a case simply because you cannot name the product. A detailed breakdown of the implicated formulas is available in our guide to NEC formula claims and counsel options.

Who Qualifies to File

Law firms screening these cases look for a consistent pattern: a premature or low-birth-weight infant who was fed cow's-milk-based Similac or Enfamil products, who was then diagnosed with NEC — confirmed by imaging or surgical findings — and who suffered serious harm: surgery, prolonged hospitalization, lasting injury, or death. The feeding must have occurred before the NEC diagnosis, and NICU records must document the timeline.

Two realities narrow the field. First, statutes of limitations apply, though many states toll (pause) the deadline for minors — in some states, the clock does not start running until the child reaches adulthood, while in others a parent's claim has its own shorter deadline. This is highly state-specific and worth clarifying immediately. Second, causation: infants who received only human milk, or whose NEC has a clearly documented unrelated cause, are unlikely to qualify. Because these cases turn on medical records, firms typically have nurses or physicians review files before accepting a case — a process explained in our Similac and Enfamil claims explainer.

Key Facts

  • The federal NEC formula cases are consolidated as MDL No. 3120 in the Northern District of Illinois.
  • Defendants are Abbott Laboratories (Similac) and Mead Johnson (Enfamil), over cow's-milk-based preterm infant formulas.
  • The core allegation is failure to warn hospitals and parents of the NEC risk in premature infants — not that formula is defective for all infants.
  • Bellwether trials are scheduled or underway in 2026, and their verdicts will shape settlement negotiations across the MDL.
  • NEC is confirmed by abdominal X-ray showing gas in the bowel wall; severe cases require surgery and can cause lifelong complications.

Who Benefits From This — and Who Does Not

Who benefits most from this guide:

Parents of a premature infant who developed NEC after cow’s-milk formula feeding in the NICU. How: The federal cases are consolidated in MDL No. 3120 in the Northern District of Illinois and concern Similac products made by Abbott Laboratories and Enfamil products made by Mead Johnson: the guide explains the claims, the products named, and who may qualify.

Parents who do not know which formula brand was used. How: Hospital feeding records document exactly which products were given and when, and a lawyer can obtain them: not knowing the brand does not by itself defeat a claim.

Families who check their deadlines promptly. How: Many states pause (toll) the statute of limitations for injured minors, sometimes until the child reaches adulthood, though parents’ own claims may have shorter deadlines: a prompt legal evaluation of deadlines matters.

Who does not benefit:

Families of term infants fed standard formula do not benefit from these claims: the cases focus on cow’s-milk-based preterm and specialized infant formulas, not standard term-infant formulas.

Families expecting a class-action payout do not benefit from that expectation: the MDL coordinates pretrial proceedings, but each family keeps an individual lawsuit decided on its own facts, and most settlements are confidential.

Families whose child never developed NEC do not benefit from an NEC claim: the litigation centers on necrotizing enterocolitis, a serious intestinal disease, not on ordinary feeding difficulties.

Related reading: our Ozempic lawsuit guide.

Frequently Asked Questions

Is the NEC baby formula lawsuit a class action?

No. The federal cases are in multidistrict litigation (MDL No. 3120), where each family keeps an individual lawsuit. The MDL coordinates pretrial proceedings, but every case is decided on its own facts — the severity of the child's injury, the feeding history, and the medical evidence.

Which formulas are named in the NEC lawsuits?

The cases concern cow's-milk-based preterm and specialized infant formulas: Similac products made by Abbott Laboratories and Enfamil products made by Mead Johnson. Standard term-infant formulas are not the focus of these claims.

My baby was fed formula in the NICU but I don't know which brand. Can I still file?

Yes, potentially. Hospital feeding records document exactly which products were given and when, and your lawyer can obtain them. Do not assume you lack a claim because you cannot name the formula — the records usually answer that question.

Is it too late to file an NEC formula lawsuit in 2026?

Possibly not. Many states pause (toll) the statute of limitations for injured minors, sometimes until the child reaches adulthood — though parents' own claims may have shorter deadlines. Because the rules are state-specific, get a legal evaluation of your deadlines promptly rather than assuming time has run out.

Have there been verdicts in NEC formula cases?

Yes — individual cases tried in state courts have produced verdicts for plaintiffs, which drew national attention to the litigation. Results have varied by case, which is why the MDL bellwether trials are the most-watched events in 2026. Compensation varies widely by case, and most settlements are confidential.

Who benefits most from the NEC baby formula lawsuits in 2026?

Parents of premature infants who developed NEC after cow's-milk formula feeding in the NICU benefit most: the federal cases sit in MDL No. 3120 and name Similac products by Abbott and Enfamil products by Mead Johnson. Parents who do not know the brand also benefit, since hospital feeding records answer that question, as do families who check tolled deadlines for minors promptly.

Who is not eligible for an NEC formula claim?

Families of term infants fed standard formula are generally not the focus of these claims, which concern preterm and specialized formulas. Families expecting a class-action payout are not eligible for that expectation, since each case is individual and most settlements are confidential, and families whose child never developed NEC do not have an NEC claim.

How do I start an NEC formula claim?

Gather the NICU feeding records, which document exactly which products were given and when, and note the dates of the NEC diagnosis and treatment. Then get a prompt legal evaluation of your state's deadlines, since minors' claims are often tolled but parents' own claims may be shorter. Do not assume that not knowing the brand means you have no claim.

Disclaimer: This article is for general information only and is not legal or financial advice. Laws, policies, and figures change over time — verify current rules with a qualified professional before acting.

Watch on YouTube

Problem Solved on YouTube